Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150
Benzinga Newsdesk 20 hours ago
Analyst RatingsNewsReiterationPrice Target
Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.
Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.